RAP 0.00% 20.5¢ raptor resources limited

HomeAsian Investment Series 2019 Australia Biotech Invest &...

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
  1. 880 Posts.
    lightbulb Created with Sketch. 259

    Global Investment Event Series

    AusBiotech’s Global Investment Event Series helps Australian life sciences companies connect with global capital markets and empowers them to be competitive on a global scale by:

    • Leading Australian life sciences companies to major investment hubs around the world including Australia, Hong Kong, China, the US and Europe.
    • Arranging access to opportunities for collaboration, partnerships and alternative funding.
    • Providing investor support and education both domestically and internationally.

    The AusBiotech-led Global Investment Program aims to improve management and workforce skills. AusBiotech is working with consortium partners the ASX, DibbsBarker, WE Buchan and KPMG, all of which bring extensive insight and experience in the life sciences to enhance the capability of the sector to engage with international markets and access global supply chains.

    This venture has received funding through the MTPConnect Project Fund Program – a dollar-for-dollar matched program investing in big, bold ideas to improve the productivity, competitiveness and innovative capacity of Australia’s medical technology, biotechnology and pharmaceutical sector, supported by the Australian Government Industry Growth Centres Initiative.

    Major outcomes of this program include the development and publication of a “Guide to Life Sciences Investing”, the development and delivery of workshops for “Roadmap to preparing for a successful IPO” and “Pitching to Investors” and the upscaling and enhancement of AusBiotech’s current global investment event series.

    In 2017, the AusBiotech-led Asian Investment Series confirmed that investor interest in the Australian life science industry is strong and intensifying.

    Almost 400 delegates gathered to hear 21 Australian biotechnology and medical technology companies present their investment proposition as part of the Series, which was held in Singapore, Hong Kong and Shanghai during March.

    AusBiotech's former CEO, Glenn Cross, who led the three events, said: "This strong investor interest in the Australian life sciences stems from the nation's top ranking in the global life sciences and its diverse suite of investment opportunities in biotechnology and pharmaceuticals."

    Read the article, Asian Investor series confirms strong investor interest.

    The events featured:

    • Biotech and medtech company spotlight presentations
    • Networking sessions
    • A business matching program to set up one-on-one meetings
    • Well-researched, high-quality program that covers relevant trends in biotech investment globally
    • Local and international speaker line-up of experts who are at the forefront of biotech investing and partnering
    • Professional investors looking for promising biotech investment opportunities.

    Guide to Life Sciences Investing

    There has been an increase in investment into life sciences companies and technologies in recent years. Yet investor hesitancy remains, as information regarding the sector is often highly complex, unconsolidated and difficult to access.

    This Guide will build an improved understanding of the unique life sciences sector to increase quantity and quality of investment in life sciences companies.

 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.